HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2029

Conditions
ADPKD
Interventions
DRUG

Hydrochlorothiazide 25 mg

An oral capsule containing 25mg of hydrochlorothiazide

DRUG

Placebo

A matching oral capsule containing placebo

Trial Locations (13)

Unknown

Cliniques Universitaires Saint-Luc, Brussels

University Hospital Leuven, Leuven

Hospital La Cavale Blanche, Brest

Necker-Enfants Malades Hospital, Paris

Charité University Hospital, Berlin

University Hospital Cologne, Cologne

Med. Klinik und Poliklinik III, Universitätsklinikum Dresden., Dresden

Amsterdam University Medical Center, Amsterdam

University Medical Center Groningen, Groningen

Erasmus University Medical Center, Rotterdam

Fundación Puigvert, Barcelona

Addenbrooke's Hospital, Cambridge

University of Sheffield Medical School, Sheffield

All Listed Sponsors
lead

University Medical Center Groningen

OTHER

NCT05373264 - HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life | Biotech Hunter | Biotech Hunter